Signature abnormalities in the cell cycle and apoptotic pathway have been identified in mantle cell lymphoma (MCL), affording the opportunity to develop targeted therapies. In this study, we tested a novel class of kinase inhibitors, styryl sulfones, which differ from prior cell cycle inhibitors in that they are not related to purines or pyrimidines. We observed that two closely related compounds, ON013100 and ON01370, altered the growth and cell cycle status of MCL lines and potently inhibited the expression of several important molecules, including cyclin-dependent kinase4, p53, mouse double minute 2 (MDM2), and cyclin D as well as increased cyclin B expression. Using both terminal deoxy transferase uridine triphosphate nick end-labelling and poly ADP-ribose polymerase assays, we found that these compounds caused apoptosis in MCL cells. In addition, using molecular analyses, we observed the modulation of caspase-3 activity but not the expression of B-cell lymphoma family molecules. Next, we investigated the cytotoxicity of the MCL lines upon treatment with styryl sulfone compounds in combination with other currently used chemotherapeutic agents, such as doxorubicin (DOX) or vincristine (VCR). We found that the combination of DOX plus styryl sulfone or VCR plus styryl sulfone increased cytotoxicity by one log scale, compared with the single styryl sulfone compound. Thus, styryl sulfones alone, or in combination with chemotherapeutic agents, present attractive opportunities for new drug development in MCL.
Introduction
Mantle cell lymphoma (MCL) accounts for about 6-8% of all lymphoid neoplasms and exhibits the phenotype of a B-cell lymphoma (Bcl), expressing CD19, CD20, CD22, CD79a and CD5 (Campo et al., 1999; Swerdlow and Williams, 2002) . The two major histopathological types of MCL include a classical subtype with small to medium sized neoplastic cells and a blastoid subtype with larger, pleiomorphic or lymphoblast-like cells (Lardelli et al., 1990; Tiemann et al., 2005) . The vexing problem with MCL is that although patients may initially respond to chemotherapy, they have a very high rate of relapse, even after bone marrow transplantation, with median survival on the order of 3-4 years (Zucca et al., 1995; Witzig, 2005) .
MCL has signature chromosomal abnormalities that result in the upregulation of cyclin D1. Normally, cyclin D1 associates with cyclin-dependent kinase (CDK)4 and CDK6 to form a key driver of the G1 phase of the cell cycle (Bosch et al., 1994; Hunter and Pines, 1994; de Boer et al., 1995; Ferbabdez et al., 2005) . Primary alterations in the DNA damage response pathway involve reduced ataxia telangiectasia mutated (ATM) kinase, inactivation of checkpoint kinase (CHK)-1 and -2 that act downstream of ATM, and increased MDM2 which reduces p53 (de Leeuw et al., 2004; Ferbabdez et al., 2005; Rizzatti et al., 2005) . Initial studies of MCL suggested that the level of cyclin D1 expression is closely correlated with the proliferative rate of the malignant cells (Rosenwald et al., 2003; Kimby et al., 2005) . A cascade of alterations also can occur with other cell cycle inhibitors such as p27kip1 and p21. These changes result in the increased kinase activity of cyclin E/CDK2 complexes that promote S-phase entry by phosphorylating the retinoblastoma (Rb) protein, as well as in activation of the phosphatidylinositol 3 0 -kinase-AKT survival pathway (Ferbabdez et al., 2005; Rizzatti et al., 2005) . The dysregulation of cell cycle proteins and alteration in the cellular response to DNA damage in MCL afford attractive targets for new drug development.
Styryl sulfones, which constitute a novel family of non-ATP-competitive antineoplastic agents, are currently being tested in early stage clinical trials (Gumireddy et al., 2005) . According to the report, another non-ATP-competitive styryl sulfone, ON01910, functioned as a potent anticancer agent by inducing mitotic arrest of tumor cells leading to their apoptosis (Gumireddy et al., 2005) . Thus, we conducted a blind screen of non-ATP-competitive styryl sulfones against well-characterized MCL cell lines and observed that two styryl sulfone compounds, ON013100 and ON01370 (Figure 1 ), had potent effects in blocking cell growth and altering the cell cycle.
Results

Styryl sulfones alter the MCL cell cycle
Twenty styryl sulfone compounds were tested blindly with respect to alteration of cell cycle progression in MCL cell lines. To this end, Granta 519 cells were treated with 1 mM of each compound for 24 h, and the cells were examined by flow cytometry. As shown by the fluorescence-activated cell sorter (FACS) analyses, ON013100 and ON01370 significantly altered the cell cycle profile, dramatically increasing the number of cells in G2/M phase (Figure 2) . Treatment of the cells with these compounds also downmodulated G1/S phase ( Figure 2 ). In contrast, eighteen other compounds did not induce any changes in the cell cycle profile, compared with the control. One of the eighteen, ON56050, was then used as a control in subsequent studies. Similar results were obtained when Granta 519 cells were treated with this compound for 1 h followed by a 24 h culture in complete Roswell Park Memorial Institute (RPMI)-1640 media. Treatment of the cells with even 0.1 mM of ON013100 or ON01370 resulted in an arrest of the G2/M phase of the cell cycle (data not shown). Similar results were obtained in the Z138C cell line (data not shown). Taken together, our data demonstrate that certain styryl sulfone compounds can impede cell cycle progression by arresting MCL cells at the G2/M phase predominantly. Styryl sulfones alter the expression of protein molecules involved in the cell cycle In order to elucidate the molecular mechanisms involved in the observed cell cycle alterations, we investigated the effect of the styryl sulfones ON013100 and ON01370 on the expression of protein molecules important for cell cycle regulation. As one of the distinct features of MCL is overproduction of cyclin D1 (Bosch et al., 1994; Hunter and Pines, 1994; de Boer et al., 1995; Ferbabdez et al., 2005) , we first examined changes in the expression of this molecule in Granta 519 and Z138C cells upon treatment with the styryl sulfones. We found that expression of the cyclin D1 molecule was inhibited in the presence of ON013100 and ON01370 (Figure 3 ), corroborating the cell cycle analysis in Figure 2 . As cell cycle regulation by cyclin D1 is achieved by its interaction with CDK4 or CDK6 (Ely et al., 2005) , we next investigated the level of CDK4 expression in these cells following treatment with the above compounds. As shown, we also observed decreased CDK4 expression in the Granta 519 and Z138C cells upon stimulation with the two synthetic agents (Figure 3 ). Interestingly, the expression level of Rb, whose activity is regulated by cyclin D1/CDK4 complexes, was unchanged when the cell lines were treated with either ON013100 or ON01370 (Figure 3 ), although the phosphorylation status of Rb is unknown. It is known that overexpression of cyclin D1 plays an important role in controlling the G1 progression and G1/S transition of the cell cycle (Sherr and Roberts, 1999; Kozar et al., 2004; Sherr and Roberts, 2004) . Furthermore, p53 has been reported to be involved in regulating the G1 and G2 phases of the cell cycle (Serrano et al., 1993; Lee et al., 2001; Boutros and Byrne, 2005) and has also been employed as a prognostic marker in MCL (Chiarle et al., 2000) . Thus, we investigated changes in p53 expression in Granta 519 and Z138C cells in the presence of ON013100 or ON01370 and found that p53 expression was decreased ( Figure 3) . Similarly, expression of p21 molecule was also decreased in the presence of these two compounds ( Figure 3 ). To assess whether this decrease might occur in association with changes in p53 regulation, we assayed the protein levels of MDM2, which controls the stability of p53. We found that MDM2 expression was also significantly reduced upon treatment of the cells with either agent (Figure 3 ). As our cell cycle data showed that the agents modulated the cell cycle at the G2/M phase, we also examined the expression of cyclin B1 (which is important in regulating progression through G2 and M phases of the cell cycle) (Chiarle et al., 2000; Fukuda et al., 2005) . Our data showed that cyclin B1 expression was enhanced following treatment with ON013100 or ON01370 ( Figure 3 ). However, expression of Cdc2 p34, an important regulator of the G2/M checkpoint, was decreased ( Figure 3 ). The observed changes in the expression of these proteins were not due to disparities in sample loading, as the amount of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) internal control was unchanged. Taken together, our data suggest that the observed cell cycle alteration in the presence of these styryl sulfones may be due to the modulated expression of intracellular proteins involved in cell cycle regulation.
Cytotoxic effects of test compounds
We then examined whether ON013100 and ON01370 induce cell death. The assay showed that both Granta 519 and Z138C cell viability was not significantly affected by these two compounds when the cells were treated for 24 h (Figure 4 ). However, the trypan blue dye exclusion assay showed pronounced cell death when the cells were treated for 48 h with as little as 0.4 mM of each compound (Figure 4 ), indicating that these agents were cytotoxic to the MCL lines. We next investigated whether the observed cytotoxicity was due to apoptosis, by using a terminal deoxy transferase uridine triphosphate nick end-labelling (TUNEL) assay. We found that both of the compounds caused significant apoptotic depletion of the Granta 519 cells at 48 h. For instance, Granta 519 cells treated with 0.01 mM ON013100 (Figure 5a (i) ) or ON01370 (Figure 5b (i) ) showed 38 and 17% apoptosis, respectively. Moreover, the Granta 519 cells treated with ON013100 exhibited significant apoptosis even at 0.01 mM of the compound. Similar results were obtained with the Z138C cells (data not shown), demonstrating that the styryl sulfones kill MCL cells via apoptosis.
Next, we investigated the cytotoxic effects on Granta 519 and Z138C cells upon treatment with styryl sulfone compounds in combination with other currently used chemotherapeutic agents, such as doxorubicin (DOX) and vincristine (VCR). As shown in Figure 6 , the potency of cytotoxicity was increased approximately by one log scale, compared with the cytotoxicity observed when the cells were treated with a single styryl sulfone compound (Figure 4 ).
Molecular mechanism of styryl sulfone-induced apoptosis As p53 protein expression declined upon treatment with both ON013100 and ON01370, and p53 appears to play an important role in Bax-or Bcl2-mediated apoptosis (Crowe and Sinha, 2005; Tan et al., 2005) , we examined the level of Bax expression in Granta 519 and Z138C cells following treatment with these compounds. We noted that the expression of Bax was essentially unchanged in the cells (Figure 7a ), even after treatment with the compounds for 48 h. As shown in Figure 7a , the expression of Bcl2 and Bcl-xL was also unchanged. We next explored whether the apoptosis might occur via the caspase pathway. Signals from apoptotic molecules, either in the cytoplasm or the mitochondria, eventually converge at the caspase-9 and/or caspase-3 pathways (Braday et al, 2005; Martin and Ouchi, 2005) . When the cells were untreated, precursor caspase-3 was unprocessed ( Figure 7b ). However, upon treatment of the cells with either ON013100 or ON01370, the precursor protein was processed, as evidenced by the appearance of the smaller cleaved product (arrow) and by the decreasing amounts of the precursor molecule ( Figure 7b ). We next assessed the processing of caspase-9 in the presence of these compounds. The expression and processing of the precursor caspase-9 were unaltered (data not shown). Activated caspase-3 facilitates apoptosis by inducing the cleavage of poly ADP-ribose polymerase (PARP) molecules (Brauns et al., 2005) . We found that upon ON013100 and ON01370 treatment of Granta 519 and Z138C cells, the expression and processing of 116 kDa PARP were dramatically augmented; the intensity of the PARP protein band was much stronger and the ratio of the cleaved product (85 kDa) to the precursor protein (116 kDa) was significantly increased, as compared with the untreated control sample (Figure 7b ). These data indicate that the styryl sulfones triggered apoptosis in the MCL lines via caspase-3, rather than Bcl family molecules.
Effect of a caspase-3 inhibitor on styryl sulfone-mediated apoptosis As our earlier data showed that caspase-3 plays an important role in styryl sulfone-mediated apoptosis in MCL lines, we examined whether the observed apoptosis was solely due to activation of the caspase-3 molecule. To this end, Granta 519 cells were treated with the styryl sulfone compounds ON013100 or ON01370 in the presence of a caspase-3 inhibitor or control inhibitor, and then the degree of apoptosis was Evaluation of novel sulfonyl compounds in mantle cell lymphoma I-W Park et al determined by TUNEL assay. We found that the caspase-3 inhibitor significantly blocked but did not completely abrogate the Granta 519 cell apoptosis induced by ON013100 or ON01370 (Figure 8 ). For instance, apoptotic cell death was significantly reduced from 33 to 13%, when Granta 519 cells were treated with 5 mM of caspase-3 inhibitor in the presence of 1 mM of ON013100 (Figure 8a (i) ). Taken together, these data indicate that caspase-3 plays a critical role in apoptosis, although the involvement of other caspases cannot be excluded.
Discussion
There is currently a paucity of specific anti-MCL agents and an urgency to develop them, as individuals with MCL have one of the lowest 5-year survival rates among all types of lymphoma patients. We identified two novel synthetic styryl sulfones, ON013100 and ON01370, that had potent effects on well-characterized MCL lines. These agents altered key cell cycle regulators and induced apoptosis with activation of the caspase pathway. Our data revealed that ON013100 and ON01370 compounds, closely related chemically, targeted the cell cycle of MCL lines, causing arrest at the G2-M phase. Our investigation of the molecular mechanism of cell cycle modulation by ON013100 and ON01370 demonstrated that these compounds reduced the expression of p53. The suppression of MDM2, which regulates the stability of p53, was even more dramatic. These agents also suppressed both CDK4 and cyclin D1 expression, which are critical for regulating the cell cycle progression of the G1 phase. The CDK4/cyclin D1 complex functions as a sensor for mitogenic signals and is The expression and processing of apoptotic molecules.
(a and b) Granta 519 cells were treated with the indicated concentrations of ON013100 and ON01370. Cell lysates were prepared as described above, and the expression and processing of the indicated apoptotic molecules were analysed by Western blot analyses. Control indicates unstimulated cells. GAPDH was used as an internal control for protein loading.
necessary for activation of Rb protein (Chiarle et al., 2000) . Inactivation of Rb allows for the release and activation of E2F (Nevins et al., 1997; Yamasaki, 1998) . These actions are negatively regulated by two inhibitor families -the INK4 family, which includes p15, p16, p18 and p19, and the cyclin-dependent kinase inhibitor (CIP) family, which includes p21, p27 and p57 (Chiarle et al., 2000) . Our experiments showed that the expression of Rb per se was unchanged by the two sulfone compounds. In future studies, we will examine styryl sulfone-mediated activation of Rb and the effect of activating Rb on the regulation of the inhibitor of cyclin-dependent kinase 4 (INK4) and CIP families. Expression of p27 was significantly inhibited by treatment of both MCL lines with the two compounds, though the changes in p21 expression were nominal. Taken together, these data indicate that the two sulfone compounds modulate signaling cascades originating from cyclin D1 for the G1/S phase and from cyclin B1 for the G2/M phase.
As our flow cytometry studies clearly indicated that the initial biological effect of ON013100 and ON01370 was accumulation of cells in the G2 phase (Figure 3) , we next examined whether there were any changes in the expression of cell cycle molecules involved in regulating this phase of the cell cycle. Our data showed increased expression of cyclin B1, an important cell cycle modulator of the G2 phase (Dash and El-Deiry, 2005) , consistent with the cell cycle analysis. Furthermore, the expression of Cdc2 p34, which exerts its biologic functions of mitosis and proliferation in tumor cells in combination with cyclins A and B that are active at the G2/M phase (Elias et al., 2005; Nozoe et al., 2005) , was significantly decreased.
In addition to modulation of the cell cycle, the styryl sulfone compounds induced apoptosis in both Granta 519 and Z138C cells. Our trypan blue dye exclusion assay showed pronounced apoptosis when the cells were treated with the compounds for 48 h, though the susceptibility of Granta 519 and Z138C cells to ON013100 and ON01370 differed, indicating that these agents were cytotoxic for the MCL lines. When these cells were treated even for 1 h with the styryl sulfone compounds in combination with other currently used chemotherapeutic agents, such as DOX and VCR, the potency of the cytotoxicity was increased approximately by one log scale, compared with the cytotoxicity observed when the cells were treated with a single styryl sulfone compound. This result indicates that these styryl sulfone compounds can be employed effectively to deplete MCL cells.
Consistent with the cytotoxicity study, the level of PARP protein expression increased when the cells were treated for 48 h, and the expressed protein was processed to an 85 kDa molecule, thereby lowering the ratio of the precursor protein (116 kDa) to the processed protein. To elucidate the molecular mechanism of the observed apoptosis, we then examined the expression level of Bax protein, a proapoptotic Bcl family molecule, in cells treated for 48 h, as p53 is known to trigger apoptosis through Bax (Crowe and Sinha, 2005; Tan et al., 2005) . The level of Bax expression was unchanged upon treatment with ON013100 or ON01370, suggesting that the observed alteration in p53 expression may not be directly linked to the apoptosis. Similarly, the expression levels of Bcl2 and Bcl-xL were not significantly influenced by treatment of the cells with the chemical agents. Altogether, these data indicate that apoptotic molecules in the mitochondria might not be crucial to styryl sulfone-induced apoptosis in MCL.
The cleavage of PARP protein is achieved by cytoplasmic caspase molecules, specifically caspases-3 and -9 (Braday et al., 2005; Martin and Ouchi, 2005) . Hence, we investigated the possible involvement of these molecules in MCL apoptosis. Caspase-9 has been reported to be activated by Bcl family molecules through a sequence of events (Choi and Singh, 2005) , and our data showed that the expression of Bcl family molecules was unaffected by treatment of the mantle cells with ON013100 and ON01370. In contrast, caspase-3 was processed by the two compounds in both cell lines, generating the cleaved product (see arrow, in Figure 7b ). Additional analyses using a caspase-3-specific inhibitor indicated that caspase-3 plays a pivotal role in the observed apoptosis, although the involvement of other caspase molecules cannot be completely excluded. Further study is needed to delineate the signaling cascade leading to the apoptosis induced by these styryl sulfone compounds.
In conclusion, two novel closely related styryl sulfone compounds, ON013100 and ON01370, were cytotoxic to mantle cells, as evidenced by apoptosis through the caspase-3 molecule and by PARP cleavage. The compounds modulated the cell cycle, specifically at the G2 phase, via altered expression of several key regulatory molecules. Previous work demonstrated that ON01910 displayed potent anticancer activity (Gumireddy et al., 2005) . As our compounds are also non-ATP-competitive small molecules, we believe, based on our preliminary results, that styryl sulfones alone, or in combination with chemotherapeutic agents, present attractive opportunities for new drug development in MCL.
Materials and methods
Antibodies
The antibodies (Abs) used for the cell cycle analysis were antip53, anti-MDM2, anti-cyclin D1, anti-CDK4, anti-Cdc2 p34, anti-p27, anti-p21, anti-cyclin B1, anti-Rb, anti-GAPDH, antiBax, anti-Bcl2, anti-Bcl-xL, anti-Caspase-3 and anti-PARP. The above Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), except for the anti-PARP Ab (BioMol, MA, USA) and anti-GAPDH Ab (Roche, Indianapolis, IN, USA).
Structures of styryl sulfone compounds
The structures of ON013100 and ON01370 are shown in Figure 1 .
Cells
Three well-characterized MCL cell lines Granta 519 and Z138C were kindly provided by Dr Michael Williams of the University of Virginia and Dr Geoffrey Shapiro of the DanaFarber Cancer Institute. These cells were cultured in complete RPMI-1640, as described (de Leeuw et al., 2004) .
Cytotoxicity assay
The cytotoxicity of the compounds was measured by counting live cells, using the trypan blue dye exclusion method.
Cell cycle analyses
To determine the effect of the indicated compounds on the cell cycle, MCL cells were treated for 24 h, and then washed and fixed with 70% ethanol. After incubation overnight at À201C, the cells were washed with phosphate-buffered saline (PBS), and then suspended in staining buffer (propidium iodide, 10 mg/ml; Tween-20, 0.5%; RNase, 0.1% in PBS). The cells were analysed with a FACS Vantage flow cytometer that uses CellQuest acquisition and analysis programs. Gating was set to exclude cell debris, cell doublets, and cell clumps.
TUNEL assay
The level of chromatin cleavage due to apoptosis was quantitated by using the Fluorescein In Situ Cell Death Detection kit (Roche, IN, USA), as described (Park et al., 2001) . To assess caspase-3-mediated apoptosis, a cell-permeable, irreversible inhibitor of caspase-3, Z-DEVD-FMK (R&D Systems, Minneapolis, MN, USA), and FMK-control (R&D Systems) were employed.
Immunoblot analyses
Cells stimulated with the indicated compounds were lysed in radioimmunoprecipitation assay buffer, and immunoblot analyses were performed, as described (Park et al., 2001) .
